Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
NCT02551159
Completed
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
09/16/2021
Locations: Research Site, Aurora, Colorado +196 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
NCT02314117
Completed
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2021
Locations: Highlands Oncology Group, Fayetteville, Arkansas +134 locations
Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
NCT02264990
Completed
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2021
Locations: Clearview Cancer Institute /ID# 131434, Huntsville, Alabama +139 locations
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
Bristol Bladder Trial
NCT01616875
Unknown
26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given intravenously on day 1 of each 3 weekly cycle prior to radical cystectomy, to evaluate the overall response rate and to determine whether this approach warrants further research of a phase II/III study.Participation in 2 sub studies will also be offered to the participants. 1. Contrast Magnetic resonance imaging (MRI )... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2020
Locations: Bristol Haematology + Oncology Centre, Horfield Road, Bristol, Not set
Conditions: Infiltrating Bladder Urothelial Carcinoma
Register for Updates
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01704716
Recruiting
This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunot... Read More
Gender:
ALL
Ages:
Between 1 month and 21 years
Trial Updated:
10/21/2020
Locations: Women and Children´s Hospital, Adelaide, Not set +125 locations
Conditions: Neuroblastoma
Register for Updates
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
NCT03116971
Terminated
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2020
Locations: Research site, Mesa, Arizona +79 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
NCT01450761
Completed
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2020
Locations: Genesis Cancer Center, Hot Springs, Arkansas +224 locations
Conditions: Small Cell Lung Carcinoma
Register for Updates
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)
NCT01993979
Unknown
POUT is a multi-centred randomised controlled phase III trial. 345 patients who have undergone nephro-ureterectomy, are surgically staged pT2-pT4, N0-3 or are pT1 and node positive, and who are fit for adjuvant chemotherapy, will be randomised to four cycles of adjuvant platinum based chemotherapy (experimental group) or surveillance (control group). Participants will be followed up according to routine practice. Primary endpoint: Disease-free survival (DFS) Secondary endpoints: * Overall Sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2020
Locations: William Harvey Hospital, Ashford-Kent, England +60 locations
Conditions: Transitional Cell Carcinoma of Ureter
Register for Updates
M6620 First in Human Study
NCT02157792
Completed
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2020
Locations: Mayo Clinic Arizona, Phoenix, Arizona +30 locations
Conditions: Advanced Solid Tumor
Register for Updates
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
NCT02357147
Terminated
This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in participants with unresectable Malignant Pleural Mesothelioma (MPM) who have not received prior systemic therapy. Per a business decision made by the Sponsor, participants who were randomized to am... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2020
Locations: Not set, La Jolla, California +48 locations
Conditions: Mesothelioma, Malignant
Register for Updates
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
NCT00388960
Completed
The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2019
Locations: Algemeen Ziekenhuis Middelheim, Antwerpen, Not set +24 locations
Conditions: Small Cell Lung Cancer
Register for Updates
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
NCT01900158
Completed
This is a Phase I Dose Escalation Study in which the safety, tolerability and efficacy of Amphinex®--induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy will be assessed in patients with advanced inoperable cholangiocarcinomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2019
Locations: CHU Angers, Angers, Maine-et-Loire +10 locations
Conditions: Cholangiocarcinoma
Register for Updates